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Key Clinical Message
The FOXP protein family (FOXP1-4) is a group of transcription factors that
play important roles in embryological, immunological, hematological, and
speech and language development. Here, we report FOXP1 de novo mutation
and severe speech delay in an individual belonging to a non-Caucasian
population.
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Introduction
The FOXP protein family (FOXP1-4) is a group of tran-
scription factors that play an important role in embryo-
logical, immunological, hematological, and speech and
language development [1]. Le Fevre et al. [2] reviewed a
total of 10 patients with de novo mutations of FOXP1
and showed that haploinsufficiencies of FOXP1 are associ-
ated with global developmental delay/mental retardation
with moderate/severe speech delay. Here, we report the
case of a Japanese female patient with severe speech delay
and the identification of a de novo FOXP1 missense
mutation by exome analysis.
Materials and Methods
Case report
The patient is a 22-year-old female and is the second-
born child of nonconsanguineous Japanese parents. She
has one healthy sister and no family history of mental
retardation. She was born by normal vaginal delivery at
34 weeks gestation, and her birthweight was 2100 g
(+0.1 SD). Her developmental delay was noted by a pedi-
atrician when the patient was 1 year old. She started to
walk alone at the age of 2. Development was globally
delayed, especially in the area of speech and language
acquisition. The patient’s hearing and vision were normal,
and no autistic features, developmental regression, or his-
tory of seizure were present. She began to menstruate at
the age of 13. At the time of examination (22 years old),
she displayed a short stature (141 cm, 3.2 SD, body
weight 44.3 kg, 1.1 SD) and delayed speech (she was
unable to speak), but her receptive language abilities were
relatively developed as indicated by her understanding of
relational concepts. She required assistance with routine
daily activities, and hyperextension of her joints was
observed. Chromosome analysis with G-banding showed
a 46, XX karyotype. Her father’s height is 171 cm and
mother’s height is 154 cm. Table 1 shows the neurodevel-
opmental features of the patient in comparison with data
presented by Le Fevre et al. [2].
This study was approved by the Ethical Committee at
the University of Tsukuba and was conducted according
to the Principles of the Declaration of Helsinki. Informed
consent was obtained from the parents.
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Sequencing
Exome sequencing was performed, following the protocol
described in the SureSelect Library prep kit (post-pool
version 4; Agilent Technologies, Inc., Santa Clara, CA).
The DNA library was subjected to emulsion PCR
(SOLiDTM EZ BeadTM Emulsifier kit; Life Technologies,
Carlsbad, CA) to generate clonal DNA fragments on
beads, followed by bead enrichment (SOLiDTM EZ BeadTM
Enrichment kit; Life Technologies). Enriched template
beads were sequenced on a SOLiD 5500xl sequencer as
single-end, 60-bp reads (Life Technologies). The SOLiD
5500xl output reads were aligned against the human gen-
ome reference sequence (hg19) using LifeScope version
2.5.1 (Life Technologies) to generate BAM files. Variant
calling was performed following the Best Practices speci-
fied in the Genome Analysis Toolkit [3] (GATK, version
2.7.4), Picard (http://picard.sourceforge.net) and SAM-
tools [4], and only reads that mapped to a unique posi-
tion in the reference genome were used.
A total of 68,391 variants were detected in the patient.
We first filtered out the variants with low-quality values
generated by GATK output, resulting in a new total of
62,200 variants. To distinguish potentially pathogenic
variants from other variants, we filtered out variants in
our in-house references (57 exome samples), public data
from dbSNP (http://www.ncbi.nlm.nih.gov/SNP/, version
137), and a 1000-genome database [5]. After this filtering
step was applied, 393 variants remained. We then used
ANNOVAR software to filter out synonymous variants
and intronic variants because they are less likely to be
pathogenic [6], which resulted in 84 remaining variants.
We then used SIFT [7], Polyphen2 [8], LRT [9], or Mu-
tationTaster [10] software to predict the potential impact
of an amino acid substitution on the function of human
proteins, and we filtered out “benign” missense mutations
as defined by the above-mentioned software. A total of 13
single-nucleotide variants and one frame-shift variant
remained after this step (Table 2).
We performed direct sequencing to evaluate these 14
candidate mutations using DNA obtained from the
patient and her parents. Among these, two mutations
(SPERT and GRP52) were not confirmed by direct
sequencing. Ten of the mutations existed in at least one
of the healthy parents, suggesting that they are unlikely to
be pathogenic. Two of the mutations, FOXP1 and
PRKAA1, were unique to the patient.
Discussion
It has been demonstrated that the use of next-generation
sequencing techniques provides a high success rate in the
diagnosis of unidentified genetic conditions. Need et al.
performed exome sequencing on DNA from 12 patients
with unexplained and apparent genetic conditions, which
resulted in a diagnosis of a likely genetic origin of the
condition in six of the 12 patients [11]. Exome sequenc-
ing has also been applied in autopsies of patients with
sudden unexplained death and has been used to success-
fully identify mutations related to cardiac arrhythmia and
cardiomyopathy [12]. Therefore, exome is becoming a
powerful tool for the diagnosis of patients with unex-
plained conditions.
The FOXP protein family (FOXP1-4) is a group of
transcription factors that play an important role in
embryological, immunological, hematological, and speech
and language development [1]. FOXP2 was the first gene
to be associated with severe speech disorders. It was
identified using a three-generation pedigree in which a
severe speech and language disorder was transmitted as
an autosomal-dominant monogenic trait [13]. Subse-
quently, many de novo and familial cases of severe
speech disorders associated with FOXP2 mutations have
been reported, and mutations in FOXP2 are well known
to cause developmental speech and language disorders
[14].
Table 1. Comparison of the neurodevelopmental features reported
by Le Fevre et al. [2] and the patient in this study.
Symptoms Le Fevre et al. [2] Index case
De novo mutation 5/5 +
Low birthweight 1/3 +
FTT or small for age 2/6 
Obesity 2/6 
Prominent forehead 4/8 +
Down slanted palpebral fissures 3/8 
Short nose with broad tip 5/8 +
Frontal hair upsweep 2/8 +
Prominent digit pads 2/8 
Single palmar creases 2/8 
Clinodactyly 2/8 
Congenital malformation 4/9 
Global delay 10/10 +
Regression 1/2 
Intellectual delay 8/8 +
Gross motor delay 9/9 +
Speech and language delay 10/10 +
Expressive language more severely
affected than receptive language
7/7 +
Articulation consonants 5/5 None
Poor grammar 4/4 None
Oro-motor dysfunction 3/7 
Autistic feature 3/4 
Autism 2/4 
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Because FOXP1 and FOXP2 form heterodimers for
transcriptional regulation, it has been suggested that they
cooperate in common neurodevelopmental pathways
through the coregulation of common targets [15]. Vernes
et al. screened for mutations in FOXP1 genes with a
denaturing high-performance liquid chromatography
method using DNA from 49 patients with developmental
verbal dyspraxia. They found one missense mutation
(P215A) in one patient, but P215A was also identified in
an unaffected sibling of the patient [16], which suggests
that P215A is unlikely to be pathogenic. Hamdan et al.
identified two patients with de novo FOXP1 mutations
that caused haploinsufficiency and suggested that
decreased expression of FOXP1 has a more global impact
on brain development than does decreased expression of
FOXP2 [17]. Subsequently, mutations in FOXP1 have
been reported to be associated with global developmental
delay, intellectual disability, and speech defects [2, 17–21].
As noted by Le Fevre et al., the most consistent feature of
a FOXP1 mutation is global developmental delay with
prominent speech delay, which was also observed in the
present case study. To the best of our knowledge, this is
the first report of a FOXP1 de novo mutation in an indi-
vidual with severe speech delay who belongs to a non-
Caucasian population. All of the previously reported
FOXP1 mutations as well as the one in this study
occurred de novo, suggesting that haploinsufficiency of
FOXP1 reduces fitness. In addition, some characteristic
features of FOXP1 mutations, such as speech delay, a
prominent forehead, a short nose with a broad tip, and
frontal hair upsweep, were concordant with the pheno-
type of the patient in this study.
PRKAA1 is a catalytic subunit of the 50-prime-AMP-
activated protein kinase (AMPK). AMPK is a cellular
energy sensor conserved in all eukaryotic cells, and AMPK
regulates the activities of a number of key metabolic
enzymes through phosphorylation. Variations in PRKAA1
have been reported to be associated with diabetes [22],
cancer [23–25], coronary artery disease in type 2 diabetes
[26], and open-angle glaucoma [27]. However, no reports
have shown an association between PRKAA1 mutations
and developmental delay. Although mutations in PRKAA1
or other genes may contribute to the patient’s symptoms,
it appears likely that the patient’s severe speech delay may
have been caused by a de novo missense mutation of the
FOXP1 gene based on results of previous studies. Next-
generation sequencing techniques can provide informa-
tion that is essential for the molecular diagnosis of
patients with unexplained conditions.
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